View in EDS HTML Full Text PDF Full Text

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.

Saved in:
Bibliographic Details
Title: New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
Authors: Tada, Toshifumi1,2 (AUTHOR) tadat0627@gmail.com, Kumada, Takashi3 (AUTHOR), Hiraoka, Atsushi4 (AUTHOR), Kariyama, Kazuya5 (AUTHOR), Tani, Joji6 (AUTHOR), Hirooka, Masashi7 (AUTHOR), Takaguchi, Koichi8 (AUTHOR), Atsukawa, Masanori9 (AUTHOR), Fukunishi, Shinya10 (AUTHOR), Itobayashi, Ei11 (AUTHOR), Tsuji, Kunihiko12 (AUTHOR), Tajiri, Kazuto13 (AUTHOR), Ochi, Hironori14 (AUTHOR), Ishikawa, Toru15 (AUTHOR), Yasuda, Satoshi16 (AUTHOR), Ogawa, Chikara17 (AUTHOR), Toyoda, Hidenori16 (AUTHOR), Hatanaka, Takeshi18 (AUTHOR), Nishimura, Takashi1 (AUTHOR), Kakizaki, Satoru19 (AUTHOR)
Source: Cancer Medicine. Mar2023, Vol. 12 Issue 6, p6980-6993. 14p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20457634
DOI:10.1002/cam4.5495